Switch theme
Sign up to access all valuation multiples
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz’s total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe’s first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.
1996
23.4K+
LTM Revenue $9.1B
LTM EBITDA $1.8B
$25.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sandoz has a last 12-month revenue (LTM) of $9.1B and a last 12-month EBITDA of $1.8B.
In the most recent fiscal year, Sandoz achieved revenue of $12.5B and an EBITDA of $891M.
Sandoz expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sandoz valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.1B | XXX | $12.5B | XXX | XXX | XXX |
| Gross Profit | $4.4B | XXX | $5.9B | XXX | XXX | XXX |
| Gross Margin | 49% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | $1.8B | XXX | $891M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 7% | XXX | XXX | XXX |
| EBIT | $1.6B | XXX | $369M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $322M | XXX | n/a | XXX | XXX | XXX |
| Net Margin | 4% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $4.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sandoz's stock price is CHF 42 (or $50).
Sandoz has current market cap of CHF 18.0B (or $21.6B), and EV of CHF 21.0B (or $25.2B).
See Sandoz trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25.2B | $21.6B | XXX | XXX | XXX | XXX | $3.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sandoz has market cap of $21.6B and EV of $25.2B.
Sandoz's trades at 2.0x EV/Revenue multiple, and 28.3x EV/EBITDA.
Equity research analysts estimate Sandoz's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sandoz has a P/E ratio of 55.9x.
See valuation multiples for Sandoz and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21.6B | XXX | $21.6B | XXX | XXX | XXX |
| EV (current) | $25.2B | XXX | $25.2B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 11.4x | XXX | 28.3x | XXX | XXX | XXX |
| EV/EBIT | 13.1x | XXX | 68.5x | XXX | XXX | XXX |
| EV/Gross Profit | 4.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 55.9x | XXX | 233.4x | XXX | XXX | XXX |
| EV/FCF | 82.3x | XXX | 350.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSandoz's last 12 month revenue growth is 0%
Sandoz's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Sandoz's rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sandoz's rule of X is 22% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sandoz and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | -5% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 48% | XXX | XXX | XXX |
| Rule of 40 | 9% | XXX | 8% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 22% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sandoz acquired XXX companies to date.
Last acquisition by Sandoz was XXXXXXXX, XXXXX XXXXX XXXXXX . Sandoz acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sandoz founded? | Sandoz was founded in 1996. |
| Where is Sandoz headquartered? | Sandoz is headquartered in Switzerland. |
| How many employees does Sandoz have? | As of today, Sandoz has 23.4K+ employees. |
| Is Sandoz publicy listed? | Yes, Sandoz is a public company listed on SWX. |
| What is the stock symbol of Sandoz? | Sandoz trades under SDZ ticker. |
| When did Sandoz go public? | Sandoz went public in 2023. |
| Who are competitors of Sandoz? | Similar companies to Sandoz include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sandoz? | Sandoz's current market cap is $21.6B |
| What is the current revenue of Sandoz? | Sandoz's last 12 months revenue is $9.1B. |
| What is the current revenue growth of Sandoz? | Sandoz revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Sandoz? | Current revenue multiple of Sandoz is 2.3x. |
| Is Sandoz profitable? | Yes, Sandoz is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sandoz? | Sandoz's last 12 months EBITDA is $1.8B. |
| What is Sandoz's EBITDA margin? | Sandoz's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Sandoz? | Current EBITDA multiple of Sandoz is 11.4x. |
| What is the current FCF of Sandoz? | Sandoz's last 12 months FCF is $256M. |
| What is Sandoz's FCF margin? | Sandoz's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Sandoz? | Current FCF multiple of Sandoz is 82.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
